Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment.

Citation data:

Molecular psychiatry, ISSN: 1476-5578, Vol: 20, Issue: 10, Page: 1188-96

Publication Year:
2015
Usage 1093
Abstract Views 1029
Full Text Views 54
Link-outs 10
Captures 332
Readers 318
Exports-Saves 14
Social Media 24
Tweets 22
Shares, Likes & Comments 2
Citations 71
Citation Indexes 71
Repository URL:
https://ro.ecu.edu.au/ecuworkspost2013/890; https://publications.csiro.au/rpr/pub?list=SEA&pid=csiro:EP144218
PMID:
25349172
DOI:
10.1038/mp.2014.127
Author(s):
Cheng, L; Doecke, J D; Sharples, R A; Villemagne, V L; Fowler, C J; Rembach, A; Martins, R N; Rowe, C C; Macaulay, S L; Masters, C L; Hill, A F; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group Show More Hide
Publisher(s):
Springer Nature; Nature Publishing Group
Tags:
Biochemistry, Genetics and Molecular Biology; Medicine; Neuroscience; Cognitive Neuroscience; Diagnosis; Medicine and Health Sciences
Most Recent Tweet View All Tweets
article description
There is no consensus for a blood-based test for the early diagnosis of Alzheimer's disease (AD). Expression profiling of small non-coding RNA's, microRNA (miRNA), has revealed diagnostic potential in human diseases. Circulating miRNA are found in small vesicles known as exosomes within biological fluids such as human serum. The aim of this work was to determine a set of differential exosomal miRNA biomarkers between healthy and AD patients, which may aid in diagnosis. Using next-generation deep sequencing, we profiled exosomal miRNA from serum (N=49) collected from the Australian Imaging, Biomarkers and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR; N=60), with predictions performed using the Random Forest method. Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical and cognitive assessments, and amyloid neuroimaging with positron emission tomography were assessed. An AD-specific 16-miRNA signature was selected and adding established risk factors including age, sex and apolipoprotein ɛ4 (APOE ɛ4) allele status to the panel of deregulated miRNA resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD. Furthermore, amyloid neuroimaging information for those healthy control subjects incorrectly classified with AD-suggested progression in these participants towards AD. These data suggest that an exosomal miRNA signature may have potential to be developed as a suitable peripheral screening tool for AD.